Crinetics Pharmaceuticals (CRNX) Misses Q3 EPS by 13c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q3 EPS of ($1.38), $0.13 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $143 thousand versus the consensus estimate of $491 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
• Scorpio Tankers reports Q3 2026 TCE rates and new charters
• Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance